Cell-Free Protein Synthesis Patents: Leaders & Filing Trends 2026
A data-backed look at cell-free protein synthesis patents: who holds the ranked leadership positions, how filings trended from 2017 to 2026, which IPC classes carry the claim density, and where white space remains for ce
Filing growth = 2021 (223 records) → 2024 (139); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 6,549 records in scope (CR5), not the ranked leaders only.
What the cell-free protein synthesis patent record shows
Cell-free protein synthesis strips translation out of the living cell and runs it in a lysate or reconstituted extract, which changes what can be patented: not the organism, but the reaction chemistry, the energy regeneration system, and the extract preparation itself. The 6,549 records in scope span 2015 through the 2026 cut-off, covering academic assignees, a handful of specialist biomanufacturing firms, and large research universities filing through their own tech-transfer offices. Patent families are the fairer counting unit here because a single lab result can generate several continuation filings across jurisdictions without representing new technical ground.
The filing curve peaked in 2018 and has since narrowed, but the 2025-2026 numbers are not yet reliable signals of decline: publication lags filing by roughly eighteen months, so recent-year counts will keep rising as records catch up. Read the 2021-to-2024 comparison, not the tail, if you want a defensible growth statement.
Filing trend and technology composition
Two views of the same 6,549-record corpus: how filing volume moved year over year, and which IPC subclasses carry the claim weight once records are tagged with every class they touch.
Filing trend, 2017-2026
Volume rose from 180 filings in 2017 to a peak of 283 in 2018, then eased down; the 2021-to-2024 window shows a -38% move from 223 to 139, the most recent period without the publication-lag distortion. Years after 2024 are still filling in and should not be read as a slowdown yet.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
IPC subclass distribution
C12N (microorganisms and genetic engineering) touches 65.8% of the 6,549 records, with C12P (fermentation and enzymatic synthesis) and C07K (peptides and proteins) close behind at 43.3% and 38.1%. Because records carry multiple classes, these figures sum past 100% and should be read as claim-density signals, not as a partition of the field.
Shares are the percentage of the 6,549 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-Free Biomanufacturing: Cell-Free Protein Synthesis Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cell-free biomanufacturing: cell-free protein synthesis patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping freedom-to-operate
US9951392B2 — Substrate replenishment and byproduct removal improve yeast cell-free protein synthesis
Methods and kits are provided for calibrating a cell-free protein synthesis reaction for optimal activity. The method includes providing an extract competent for cell-free protein synthesis, performing the reaction, measuring a first end-point where synthesis plateaus, measuring a second end-point where Energy Charge declines to a defined range relative to a control extract, and adjusting Energy Charge back up to a level near that control.Filed by Northwestern University, granted 2018-04-24 — a calibration method for yeast-based extract systems rather than a composition-of-matter claim.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2000027878A1 | Screening system for zinc finger polypeptides for a desired binding ability | 1,004 |
| 2 | WO2013142578A1 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | 936 |
| 3 | WO1998031700A1 | Selection of proteins using RNA-protein fusions | 850 |
| 4 | US5674713A | DNA sequences encoding coleoptera luciferase activity | 826 |
| 5 | WO2002085923A2 | In VIVO incorporation of unnatural amino acids | 786 |
| 6 | WO2007024708A2 | RNA containing modified nucleosides and methods of use thereof | 744 |
| 7 | US20050048549A1 | Methods and agents for screening for compounds capable of modulating gene expression | 712 |
| 8 | US6258558B1 | Method for selection of proteins using RNA-protein fusions | 677 |
| 9 | WO2010037395A2 | MHC multimers in cancer vaccines and immune monitoring | 676 |
| 10 | US20030082575A1 | In vivo incorporation of unnatural amino acids | 669 |
Citation counts inside this searched corpus favour older filings by construction — a 2000-era zinc-finger screening patent will always outrank a 2023 filing on citation count alone, regardless of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four read-outs from the ranking, the trend and the class breakdown, aimed at where to file, where not to, and who else is already there.
Leadership is real but narrow
The leading assignee holds 194 records and fifth place holds 136 — a visible gap, but the top 5 combined still account for only 12.1% of the corpus. The remaining ranked leaders and the long tail beyond them hold the bulk of the field, which means no single lab's claim set defines freedom-to-operate here.
Read 2021-2024, not the tail
The complete-year comparison shows filing volume easing back over three years after the 2018 peak of 283. Years beyond 2024 are still under-reported because publication lags filing by about 18 months, so treat any apparent 2025-2026 drop as an artefact of timing, not of activity.
Extract and organism engineering is the crowded core
C12N appears on nearly two-thirds of the corpus, with C12P and C07K also above a third each. A61P, therapeutic activity of compounds, sits at just 9.2% — the thinnest of the tracked classes and a marker of where downstream therapeutic application claims remain comparatively open.
Multi-jurisdiction filing is standard practice here
With US, EPO, WIPO, Australian and Canadian receiving offices all carrying substantial volume, assignees in this space are routinely pursuing broad geographic coverage rather than filing domestically only — a sign that the leading players see commercial value across multiple markets, not just their home jurisdiction.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-free biomanufacturing: cell-free protein synthesis patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| The Regents of the University of California | The Scripps Research Institute | 27 |
| Northwestern University | Cornell University | 19 |
| The University of Tokyo | PeptiDream Inc. | 18 |
| The University of Tokyo | Gene Frontier Corporation | 16 |
| Northwestern University | LanzaTech, Inc. | 16 |
| The Board of Trustees of the Leland Stanford Junior University | SWARTZ JAMES ROBERT | 15 |
| The Regents of the University of California | University of Washington | 14 |
| RIKEN Co., Ltd. | YOKOYAMA SHIGEYUKI | 14 |
Co-assignee pairs are few — 10 recorded pairs — but the strongest ties run between university groups working the same extract chemistry, suggesting collaboration clusters around specific technical problems rather than broad institutional alliances.
Where to take this analysis
The ranking and the class breakdown tell you where claims already sit. The next step is testing a specific claim idea against that density before committing search or drafting time.
Stress-test a claim against the crowded core
C12N and C12P carry the heaviest claim density in this corpus. Before drafting around extract preparation or energy regeneration, check what's already claimed in those subclasses specifically, not just at the corpus level.
Explore in Eureka →Track the under-claimed branches
A61P sits well below the other tracked classes. If your work touches downstream therapeutic application of cell-free-made proteins, that gap is worth a closer, record-level look rather than a corpus-level assumption.
Run a white space search →Common questions on cell-free protein synthesis patents
The dataset behind this landscape contains 6,549 published records matching cell-free protein synthesis search terms, covering filings from 2015 through the 2026 data cut-off. That figure counts documents, not distinct inventions, since a single invention can generate several continuation or multi-jurisdiction filings. Patent families are the more reliable unit if you're trying to gauge how many genuinely distinct technical approaches exist rather than how many documents were filed.
The assignee ranking covers 100 companies and institutions, with the leader holding 194 records and the fifth-ranked entity holding 136. The top 5 combined account for 12.1% of all 6,549 records in scope, which means leadership is visible at the very top but far from dominant — the majority of filings sit outside the top 5. University tech-transfer offices and a small number of specialist biomanufacturing firms make up most of the ranked leadership.
Filing volume peaked in 2018 at 283 records and eased over the following years; comparing the two most recent complete years, 2021's 223 filings dropped to 2024's 139, a -38% move. Years after 2024 look lower still, but that's a publication-lag artefact — patent applications typically publish around 18 months after filing, so 2025 and 2026 figures will keep rising as more records surface. Treat the 2021-2024 window, not the raw tail of the chart, as the trend signal.
C12N, covering microorganisms and genetic engineering, appears on 65.8% of the 6,549 records and is the single densest class in the corpus. C12P (fermentation and enzymatic synthesis) and C07K (peptides and proteins) follow at 43.3% and 38.1%. Because a record can carry multiple IPC codes, these percentages overlap rather than sum to 100%, and they should be read as indicators of claim density per class rather than a strict partition of the technology.
US9951392B2, assigned to Northwestern University and granted in April 2018, claims a method for calibrating a cell-free protein synthesis reaction by measuring reaction end-points tied to the Energy Charge of the extract and adjusting it back toward a control level. It is a process and calibration claim specific to yeast-based extract systems, not a composition-of-matter claim on cell-free synthesis broadly. Anyone using a different extract chemistry, a different calibration metric, or a non-yeast system has room to design around it, though it is worth checking the full claim set for any broader dependent claims before assuming clear freedom-to-operate.
Research Cell-Free Biomanufacturing: Cell-Free Protein Synthesis Patent Landscape in depth with Eureka
Go past this page: query the whole cell-free biomanufacturing: cell-free protein synthesis patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.